Daily News for Dealmakers
2021 brought a flurry of #MnA activity in the life sciences sector, followed by a slowdown in 2022. Here’s why dealmaking could pick up again. deloi.tt/3PIOHZP
– Deloitte M&A (@DeloitteMnA)09:00 – Aug 31, 2022
Strategic Acquisition: Eli Lilly's potential acquisition of Scorpion Therapeutics signals a strategic move to bolster its oncology pipeline and enhance innovation capabilities. Biotech Market...
Strategic Rationale: Biogen's bid to acquire Sage Therapeutics' remaining stake aligns with its long-term strategy to expand neuroscience capabilities and strengthen its psychiatric and neurological...
Strategic Expansion: GSK's $1.15B acquisition of IDRx bolsters its gastrointestinal (GI) cancer therapy portfolio, marking a significant expansion into the oncology market. Financial Details: The...
Strategic Alignment: The acquisition aligns Intra-Cellular's neuroscience pipeline with J&J's pharmaceutical offerings, positioning J&J for growth in the $48B neuroscience market. Market Potential:...